Mississauga, ON – AstraZeneca, a global leader in biopharmaceuticals, has announced an $820 million investment to expand its research and development (R&D) facilities in Mississauga and relocate its Canadian headquarters to a larger, state-of-the-art office. The move is expected to create over 700 skilled jobs and further strengthen Ontario’s status as a global hub for biomanufacturing and life sciences.
“AstraZeneca’s investment is fantastic news for Ontario and a testament to the remarkable talent, innovation and opportunities our province offers,” said Premier Doug Ford.
The expansion aligns with the goals outlined in Ontario’s Taking Life Sciences to the Next Level strategy, enabling AstraZeneca to harness cutting-edge technologies, including artificial intelligence, digital health solutions, and computational pathology, to enhance treatments for cancer, infectious diseases, and rare conditions.
I joined @AstraZenecaCA in Mississauga to welcome a $820 million expansion of their research and development facility, which our government supported with $16.1 million through the Invest Ontario Fund.
As we continue standing up for Ontario workers, this expansion will create… pic.twitter.com/6nnudie0Ed
— Doug Ford (@fordnation) January 23, 2025
The provincial government is contributing $16.1 million to the project through the Invest Ontario Fund, demonstrating its commitment to fostering innovation and economic growth in the life sciences sector.
“Under the leadership of Premier Ford, Ontario continues to be at the forefront of life sciences innovation,” said Vic Fedeli, Minister of Economic Development, Job Creation and Trade. “AstraZeneca’s investment will not only support economic growth in Mississauga but reinforce Ontario’s position as a premier destination for domestic and international life science companies
Building on its 2023 announcement of 500 new scientific roles, AstraZeneca’s total investment in Ontario now exceeds $1.3 billion, creating over 1,200 high-value jobs across both initiatives. The Mississauga facility, a strategic clinical hub for the company, employs 1,500 people and oversees more than 210 global clinical studies.
Ontario’s life sciences sector has attracted over $6 billion in investments since 2018, with AstraZeneca’s expanded footprint in Mississauga serving as a key driver of innovation in the region. The province is home to a robust ecosystem of hospitals, universities, laboratories, and research centres, which continue to support the growth of companies like AstraZeneca.
With plans to grow its workforce to more than 2,000 employees in Mississauga and the Peel Region, AstraZeneca’s investment underscores the province’s appeal as a global destination for life sciences excellence. The Ontario government’s $146 million in investments further positions the province as a leading force in medical innovation and economic development.
This development marks a significant milestone for Ontario’s life sciences strategy, which aims to remove barriers to growth and attract international companies poised to make groundbreaking advancements in healthcare.
SOURCES Province of Ontario
Leave a Reply